INIBIDORES DE SGLT2 NA DOENÇA RENAL CRÔNICA: AVANÇOS NA NEFROPROTEÇÃO E EVIDÊNCIAS ATUAIS
LUMEN ET VIRTUS · 28.07.2026 · 17 (62) · e13887
DOI: 10.56238/levv17n62-046 ↗Kurz gefasst
Fachartikel in der Zeitschrift LUMEN ET VIRTUS, online erschienen am 28.07.2026. Verfasst von Sonia Lorena Yujra Quelali und 24 weiteren Autor:innen.
Abstract (Originalsprache)
Chronic kidney disease (CKD) is a major global public health problem due to its high prevalence, progressive decline in kidney function, and strong association with increased cardiovascular morbidity and mortality. Over the past decades, CKD management has focused primarily on controlling blood pressure, blood glucose, albuminuria, and cardiovascular risk factors through pharmacological strategies aimed at slowing disease progression. Nevertheless, many patients continue to progress to advanced stages of kidney disease, highlighting the need for more effective therapeutic approaches. In this context, sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as a major therapeutic innovation, demonstrating renal and cardiovascular benefits that extend beyond glycemic control. This study aimed to analyze the current scientific evidence regarding the use of SGLT2 inhibitors in chronic kidney disease, with emphasis on nephroprotective mechanisms, renal and cardiovascular outcomes, therapeutic safety, and implications for clinical practice. This integrative literature review adopted a qualitative and descriptive approach and was conducted through searches in the PubMed/MEDLINE, SciELO, ScienceDirect, and Cochrane Library databases using Portuguese and English descriptors combined with the Boolean operators AND and OR. The evidence analyzed indicates that SGLT2 inhibitors reduce albuminuria, slow the decline in estimated glomerular filtration rate, decrease the risk of progression to end-stage kidney disease, and reduce major cardiorenal outcomes in eligible patients with and without type 2 diabetes mellitus. It is concluded that this pharmacological class represents a fundamental component of contemporary nephroprotective strategies, and its use should be individualized, supported by the best available scientific evidence, and integrated into continuous clinical follow-up to optimize renal and cardiovascular outcomes and improve the quality of care for patients with chronic kidney disease.
Zitieren
APA
Quelali, S. L. Y., Moia, G. S., Silva, L. N. P. D., Brusamarello, G. R., Durão, G. P., Angelici, A. A., Bezerra, I. P., Oliveira, S. G., Bezerra, P. T. M., Jurdi, M. V., Amestoy, H. B., Gayer, L. K. C., Gonçalves, F. D. C., Veloso, F. J. R. N., Lima, L. M. A. D., Santos, H. P. D., Ribeiro, H. C., Souza, P. H. D., Sarturi, G., …, & Ferreira, A. S. (2026). INIBIDORES DE SGLT2 NA DOENÇA RENAL CRÔNICA: AVANÇOS NA NEFROPROTEÇÃO E EVIDÊNCIAS ATUAIS. LUMEN ET VIRTUS, 17(62), e13887. https://doi.org/10.56238/levv17n62-046
Vancouver
Quelali SLY, Moia GS, Silva LNPD, Brusamarello GR, Durão GP, Angelici AA, et al. INIBIDORES DE SGLT2 NA DOENÇA RENAL CRÔNICA: AVANÇOS NA NEFROPROTEÇÃO E EVIDÊNCIAS ATUAIS. LUMEN ET VIRTUS. 2026;17(62):e13887. doi:10.56238/levv17n62-046
BibTeX
@article{Quelali2026,
author = {Quelali, Sonia Lorena Yujra and Moia, Gustavo Salvadego and Silva, Lucas Noberto Pereira Da and Brusamarello, Gabriella Rosana and Durão, Giulia Parreira and Angelici, Angelina Arroyos and Bezerra, Iza Pereira and Oliveira, Sávio Gaspar and Bezerra, Paulo Tiago Moura and Jurdi, Maria Vodopivic and Amestoy, Hélio Bordoli and Gayer, Lucas Kerber Correa and Gonçalves, Fagner de Camargo and Veloso, Fernanda Joyce Rodrigues Noleto and Lima, Laura Maciel Alves De and Santos, Henos Pereira Dos and Ribeiro, Hilton Carlos and Souza, Pedro Henrique De and Sarturi, Giovanna and Santos, Aguida Marques Pereira Dos and Kafer, Maria Eduarda Paludo and Duarte, Vitória Canto and Siqueira, Amanda Lobo De and Silva, Emerson Zonel Inácio Da and Ferreira, Aline Slonikarz},
title = {INIBIDORES DE SGLT2 NA DOENÇA RENAL CRÔNICA: AVANÇOS NA NEFROPROTEÇÃO E EVIDÊNCIAS ATUAIS},
journal = {LUMEN ET VIRTUS},
year = {2026},
volume = {17},
number = {62},
pages = {e13887},
doi = {10.56238/levv17n62-046}
}
EUVIMED